Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
Santos JR, Domingo P, Portilla J, Gutiérrez F, Imaz A, Vilchez H, Curran A, Valcarce-Pardeiro N, Payeras A, Bernal E, Montero-Alonso M, Yzusqui M, Clotet B, Videla S, Moltó J, Paredes R. Santos JR, et al. Among authors: videla s. Open Forum Infect Dis. 2023 Oct 31;10(11):ofad542. doi: 10.1093/ofid/ofad542. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023553 Free PMC article.
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martínez E, Miranda J, Muñoz-Moreno JA, De la Torre J, Prieto A, Vilades C, Clotet B; SimplifiHAART Study Group. Bonjoch A, et al. Among authors: videla s. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):313-6. doi: 10.1097/01.qai.0000164249.33851.3a. J Acquir Immune Defic Syndr. 2005. PMID: 15980691 Clinical Trial.
Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3.
Sirera G, Videla S, López-Blázquez R, Llatjos M, Tarrats A, Castellà E, Grane N, Tural C, Rey-Joly C, Clotet B. Sirera G, et al. Among authors: videla s. J Antimicrob Chemother. 2008 Jan;61(1):191-4. doi: 10.1093/jac/dkm412. Epub 2007 Oct 31. J Antimicrob Chemother. 2008. PMID: 17977910
The changing face of HIV/AIDS in treated patients.
Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B. Llibre JM, et al. Among authors: videla s. Curr HIV Res. 2009 Jul;7(4):365-77. doi: 10.2174/157016209788680633. Curr HIV Res. 2009. PMID: 19601771 Review.
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial.
Revollo B, Blanco I, Soler P, Toro J, Izquierdo-Useros N, Puig J, Puig X, Navarro-Pérez V, Casañ C, Ruiz L, Perez-Zsolt D, Videla S, Clotet B, Llibre JM. Revollo B, et al. Among authors: videla s. Lancet Infect Dis. 2021 Oct;21(10):1365-1372. doi: 10.1016/S1473-3099(21)00268-1. Epub 2021 May 27. Lancet Infect Dis. 2021. PMID: 34051886 Free PMC article. Clinical Trial.
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL, Miró O, López S, Fuster D, Videla S, Martínez E, Garrabou G, Salas A, Côté H, Tor J, Rey-Joly C, Planas R, Clotet B, Tural C. Ballesteros AL, et al. Among authors: videla s. Antivir Ther. 2004 Dec;9(6):969-77. Antivir Ther. 2004. PMID: 15651755 Clinical Trial.
207 results